Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Working Capital to Net Assets Ratio
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. working capital to net assets ratio. Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) has a Working Capital to Net Assets ratio of 40.5% as of March 2026. Working capital of CN¥843.60 Million (current assets of CN¥1.40 Billion minus current liabilities of CN¥560.02 Million) is measured against net assets of CN¥2.08 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (2016–2025)
Working capital to net assets ratio of Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. from 2016 to 2025. This chart shows how Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at 40.5%, reflecting working capital of CN¥843.60 Million against net assets of CN¥2.08 Billion CNY. See Shandong Bailong Chuangyuan Bio-Tech Co. (605016) defensive interval to measure how many days the company can operate on defensive assets alone.
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Working Capital to Net Assets Ratio by Year (2016–2025)
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Shandong Bailong Chuangyuan Bio-Tech Co. assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 39.3% | CN¥771.38 Million | CN¥1.96 Billion | CN¥1.14 Billion | CN¥363.78 Million | ▲ +3.7 pp |
| 2024 | 35.7% | CN¥599.01 Million | CN¥1.68 Billion | CN¥901.46 Million | CN¥302.45 Million | ▲ +0.4 pp |
| 2023 | 35.3% | CN¥532.04 Million | CN¥1.51 Billion | CN¥773.74 Million | CN¥241.70 Million | ▼ -19.3 pp |
| 2022 | 54.6% | CN¥734.43 Million | CN¥1.34 Billion | CN¥855.54 Million | CN¥121.11 Million | ▼ -8.6 pp |
| 2021 | 63.2% | CN¥760.68 Million | CN¥1.20 Billion | CN¥831.89 Million | CN¥71.21 Million | ▲ +28.7 pp |
| 2020 | 34.5% | CN¥238.59 Million | CN¥691.09 Million | CN¥374.27 Million | CN¥135.68 Million | ▲ +11.9 pp |
| 2019 | 22.6% | CN¥135.17 Million | CN¥597.07 Million | CN¥280.41 Million | CN¥145.24 Million | ▼ -3.5 pp |
| 2018 | 26.1% | CN¥131.09 Million | CN¥501.71 Million | CN¥229.56 Million | CN¥98.47 Million | ▼ -1.7 pp |
| 2017 | 27.8% | CN¥121.28 Million | CN¥436.41 Million | CN¥299.68 Million | CN¥178.40 Million | ▲ +10.8 pp |
| 2016 | 17.0% | CN¥61.67 Million | CN¥362.67 Million | CN¥316.74 Million | CN¥255.06 Million | — |